BioSpace News Archive

On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced that Patrick Spangler has joined the Company as Chief Financial Officer.

- Financing in Support of Company’s Goal of Developing Targeted Therapies to Improve the Lives of Women with Cancer - Lead Investor Vivo Capital is Joined by Additional New Investors Avoro Capital Advisors, Funds and Accounts Managed by BlackRock, Deerfield Management Company and OrbiMed, and All Existing Institutional Investors

Checkpoint Surgical today unveiled a new corporate logo as the first step in its campaign to better identify the brand with its nerve care mission.

Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.

- Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, today announced a new, unified Medic

GreenLight Biosciences, Inc. , an integrated life sciences company developing RNA-based products for plant health, human health and animal health, today announced Charu Manocha as the company’s new Chief People Officer.

New data released today by the National Foundation for Infectious Diseases (NFID) showed that only 59 percent of US adults said they planned to get vaccinated against influenza (flu) during the 2020-2021 flu season.

Dr. Susan Love Foundation for Breast Cancer Research is thrilled to be celebrating Breast Cancer Awareness Month this October by moving beyond awareness and advocating for diverse breast cancer research in real people.

New Data Presented as Part of Moderated Poster Session at the Heart Failure Society of America Virtual Conference held September 30 – October 3, 2020

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the release of the final local coverage determination by Palmetto MolDx for AlloSure Heart. AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test which can identify underlying cell inj